BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22415862)

  • 21. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Expression of estrogen receptor, progesterone receptor, and human epithelial growth factor receptor 2 in breast cancer and the significance thereof: analysis of 910 cases].
    Liu RB; Zhou XH; Wang JN; Liang HZ; Li XX; Wu ZH; Ye JL; Wang SM
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3397-400. PubMed ID: 19159568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pattern of metastatic spread in triple-negative breast cancer.
    Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
    Breast Cancer Res Treat; 2009 May; 115(2):423-8. PubMed ID: 18543098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance and prognostic value of receptor conversion in hormone receptor positive breast cancers after neoadjuvant chemotherapy.
    Yang L; Zhong X; Pu T; Qiu Y; Ye F; Bu H
    World J Surg Oncol; 2018 Mar; 16(1):51. PubMed ID: 29514654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors in MNU and DMBA-induced mammary tumors in female rats.
    Alvarado A; Lopes AC; Faustino-Rocha AI; Cabrita AMS; Ferreira R; Oliveira PA; Colaço B
    Pathol Res Pract; 2017 May; 213(5):441-446. PubMed ID: 28285967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gli1 promotes cell survival and is predictive of a poor outcome in ERalpha-negative breast cancer.
    Xu L; Kwon YJ; Frolova N; Steg AD; Yuan K; Johnson MR; Grizzle WE; Desmond RA; Frost AR
    Breast Cancer Res Treat; 2010 Aug; 123(1):59-71. PubMed ID: 19902354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].
    Mu YX; Zhang P; Ma F; Yuan P; Wang JY; Xu BH; Li Q
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):506-511. PubMed ID: 30060358
    [No Abstract]   [Full Text] [Related]  

  • 29. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences.
    Giulianelli S; Riggio M; Guillardoy T; Pérez Piñero C; Gorostiaga MA; Sequeira G; Pataccini G; Abascal MF; Toledo MF; Jacobsen BM; Guerreiro AC; Barros A; Novaro V; Monteiro FL; Amado F; Gass H; Abba M; Helguero LA; Lanari C
    Int J Cancer; 2019 Oct; 145(7):1874-1888. PubMed ID: 30843188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phosphorylation code for oestrogen receptor-alpha predicts clinical outcome to endocrine therapy in breast cancer.
    Skliris GP; Nugent ZJ; Rowan BG; Penner CR; Watson PH; Murphy LC
    Endocr Relat Cancer; 2010 Sep; 17(3):589-97. PubMed ID: 20418363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
    Wei JL; Zhang JX; Fu DY
    World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
    Falck AK; Fernö M; Bendahl PO; Rydén L
    World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
    Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
    Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
    Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy.
    Schrijver WAME; Schuurman K; van Rossum A; ; Peeters T; Ter Hoeve N; Zwart W; van Diest PJ; Moelans CB
    Oncotarget; 2017 Aug; 8(33):55550-55561. PubMed ID: 28903441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.